Search Results
Your search for ,sAy matches 1449 pages
Showing 1 - 50ASCO and AI in Oncology: Rooted in Human-Centered Care
ASCO’s mission to conquer cancer through research, education, and promotion of the highest quality patient care requires curiosity, open-mindedness, and an evidence-based approach to emerging technologies. ASCO is committed to helping the oncology community understand, develop, apply, and monitor...
How AI Is Ushering in a New Era in Cancer Care
On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. Held at Google’s St. John’s Terminal office in New York City, the event brought together leaders in...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
As a Cancer Survivor, My Main Worry Now Is Affording Health Insurance
Until 3 years ago, cancer was so utterly frightening to me that I avoided discussing the disease or even mentioning the word as much as possible. I sympathized with a friend when she was diagnosed with lung cancer, but I never expected to be in her position. I’m a never-smoker, and except for a...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older. As the incarcerated population ages, cancer has become one of the greatest threats to their health. And despite the growing prevalence, cancer...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
A Serendipitous Fall May Have Saved My Life
In the spring of 2024, I was preparing to compete in a Half Ironman triathlon and was not surprised when I began experiencing tightness in my groin. I just figured it was the byproduct of specific endurance training I was doing in each discipline, including running, biking, and swimming, to get...
Global Analysis Uncovers Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
Study Confirms It’s ‘Never Too Late’ to See Survival Benefits From Quitting Smoking—Even With Late-Stage Cancer
New research published by Tohmasi et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that people with cancer who quit smoking had a much lower risk of dying within 2 years compared to those who kept smoking. Researchers followed more than 13,000 individuals with cancer,...
Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score
Studies show that if left untreated, between 20% and 40% of ductal carcinoma in situ (DCIS) lesions may evolve into invasive breast cancer over time. And, according to the American Cancer Society, women diagnosed with lobular carcinoma in situ (LCIS) have between a 7 and 12 times higher risk of...
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making
This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinical guidelines to facilitate critical clinical decision-making. Developed with Google Cloud’s Vertex ...
Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer Is Low
For individuals diagnosed with early breast cancer, the long-term risk of developing a second primary cancer is low—around 2% to 3% greater than the general population)—according to findings published by McGale et al in The BMJ. The researchers say this information can help reassure many breast...
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger
The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...
Survey Highlights Top Anxiety Points for Caregivers After a Cancer Diagnosis
New survey findings highlight that the anxiety caused by a cancer diagnosis extends far beyond just the patient diagnosed. The emotional impact is shared by caregivers and loved ones, with stress, grief, and worry over treatments, pain, and life expectancy weighing heavily on these individuals,...
Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial
In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors
Results from an international clinical trial demonstrated that DB-1310, a new antibody-drug conjugate, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non–small cell lung cancer...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
What Is the Value in Cost and Lives Saved of Cancer Screening and Prevention?
Several recent studies have shown the value of cancer screening in reducing the number of deaths from the disease. One study using computer modeling to estimate the number of cancer-related deaths that could be averted by increasing the use of U.S. Preventive Services Task Force (USPSTF)...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
Joint Clinical Practice Guideline Addresses Opioid Conversion for Patients With Cancer
Several medical organizations recently released a joint Clinical Practice Guideline to provide recommendations on opioid conversion in adults with cancer.1 ASCO, together with the Multinational Association of Supportive Care in Cancer (MASCC), American Academy of Hospice and Palliative Medicine,...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Use of Statins in CLL/SLL
Statin use during targeted therapy treatment led to a 61% improvement in the risk of dying of cancer for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the results of a study published in Blood Advances. The investigators sought to determine the...
Raising Awareness of Inflammatory Breast Cancer
In late January 2013, while playing with my young son, I noticed my left breast seemed slightly larger than my right breast. Although, at the time, I had no idea this type of swelling is a hallmark of inflammatory breast cancer, a rare and aggressive disease, I immediately made an appointment with...
Can ctDNA Monitoring Help to Predict Melanoma Recurrence?
A new study showed that approximately 80% of patients with stage III melanoma who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence. Researchers also found that the disease returned more than four times...
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral ...
Bringing Palliative Care to Every Patient With Cancer
Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
Partial-Gland Removal May Be an Option for Many Men With Prostate Cancer
A 5-year study on men that had primary partial-gland cryoablation shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function. Led by researchers at New York University Grossman School of Medicine, the study tracked the patient outcomes after...
Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
It’s a fast-paced world, no two ways about it. People move on from one event to another. We have to move on either for our own sake or the sake of someone near and dear. In the medical field, patients come and go, surgeries are performed, treatments are given, and everybody moves on. Being kind to...
I’m a 2.0 Version of Myself After Cancer
Although there’s no history of breast cancer in my family, when I was 10, my pediatrician introduced me to breast self-exams, so I would become familiar with my breasts and learn to spot any unusual changes as I got older. I remember her telling me this was an especially important exercise to do...
Understanding How Stigma and Incorrect Physician Assumptions About LGBTQ+ Patients’ Needs Contribute to Medical Mistrust
Over the past decade, ASCO has focused its resources on advancing health equity for sexual and gender minority (SGM) individuals with cancer. In 2017, the Society published a position statement “Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations,” which...
Impact of Menopausal Status on Long-Term Benefit From Antihormonal Treatment in Women With Breast Cancer
New research has shown that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, whereas the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through menopause. The results were reported in the Journal of the ...
Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology. Dr. Ürün is Professor of Medicine at the Ankara University School of Medicine in Turkey. After...
Cancer Has Plagued My Family
My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...
Ensuring an Inclusive Environment for Female Minority Oncologists
ASCO’s 2022 State of the Oncology Workforce in America report presented a dismal picture of the representation of Hispanic/Latinx oncologists in the field. According to the report, despite initiatives aimed at increasing diversity in the nearly 13,400 oncology workforce, which includes about 36%...
My Melanoma Could Have Been Prevented
I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safety and maintaining annual full-body skin exams to catch any suspicious moles or lesions that could...
Whole-Person Cancer Care: A Transformative Vision for Oncology
Guest Editor’s Note: Advances in cancer treatments have led to an increase in survival rates, but the quality of life is often diminished during survivorship. Because modifiable personal behavior contributes to health-care outcomes, interventions that support healthy behaviors may improve health...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
